Boc-Azetidine-3-carboxylic acid

Boc-Azetidine-3-carboxylic acid is a Boc-protected, cyclic amino acid building block featuring an azetidine ring and a carboxylic acid functionality at the 3-position, providing a conformationally constrained scaffold for peptide and peptidomimetic synthesis. The Boc group enables controlled handling and incorporation as an amino acid equivalent in protected-building-block workflows, while the ring structure supports downstream design of constrained backbones and sterically defined side-chain environments. Researchers commonly select this reagent when they need a robust, protected amino acid intermediate that can be converted into peptide segments or used to construct azetidine-containing analogs for structure-property studies.

1. Peptidomimetic Building Blocks

Boc-Azetidine-3-carboxylic acid is used by medicinal chemistry and peptide chemistry groups to assemble azetidine-containing peptidomimetics and constrained analogs where ring rigidity is leveraged to influence local geometry. In custom peptide synthesis and analog-development programs, the Boc protection supports standard segment coupling workflows, enabling incorporation of the azetidine residue as a defined building block rather than relying on more complex late-stage modifications. This makes the compound particularly useful for structure-activity relationship (SAR) campaigns that evaluate how backbone constraint and steric presentation affect target engagement or selectivity in chemical biology tool development.

2. Protected Amino Acid Intermediates

Boc-Azetidine-3-carboxylic acid serves as a protected amino acid intermediate for downstream conversion into activated coupling partners or peptide-ready derivatives during pharmaceutical intermediate development. Process and synthetic chemistry teams use it to prepare well-defined azetidine residues for incorporation into larger fragments, where the Boc group provides a stable protected handle for controlled reactivity management. The presence of the carboxylic acid at the 3-position supports transformation into coupling-compatible forms, allowing consistent assembly of azetidine-bearing segments for library synthesis and iterative analog generation.

3. Constrained Backbone Analog Synthesis

Boc-Azetidine-3-carboxylic acid is applied in the synthesis of conformationally constrained backbone analogs used in protein engineering research and chemical biology studies of structure-function relationships. By introducing an azetidine motif, developers can create peptide-like scaffolds with reduced conformational freedom, supporting comparative studies of how constraint alters folding propensity, presentation of functional groups, and interaction patterns in assays that rely on defined molecular architecture. This reagent is therefore commonly selected when the goal is not just to add an amino acid side chain, but to install a ring-constrained structural element into a peptide or peptidomimetic framework for systematic evaluation.

4. SAR Library Fragment Construction

Boc-Azetidine-3-carboxylic acid is frequently used for fragment-level construction of azetidine-containing libraries in research settings where multiple analogs must be generated efficiently with consistent residue identity. In parallel synthesis workflows, the Boc-protected format helps standardize the incorporation of the azetidine-3-carboxylate motif across different sequences, supporting rapid iteration of analog design. Teams building peptide libraries for hit-to-lead optimization or for mechanistic probing in chemical biology prefer this building block because it provides a clear, residue-specific handle for assembling constrained scaffolds without requiring extensive redesign of the azetidine component at later stages.

1. Oleic acid and glucose regulate glucagon-like peptide 1 receptor expression in a rat pancreatic ductal cell line

2. TMEM16F and dynamins control expansive plasma membrane reservoirs

3. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die

4. Relatedness of antibodies to peptides containing homocitrulline or citrulline in patients with rheumatoid arthritis

5. Therapeutic potential of an intestinotrophic hormone, glucagon-like peptide 2, for treatment of type 2 short bowel syndrome rats with intestinal bacterial and fungal dysbiosis